Search Results - "Jongen‐Lavrencic, M."

Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012 by Dinmohamed, A G, Visser, O, van Norden, Y, Blijlevens, N M A, Cornelissen, J J, Huls, G A, Huijgens, P C, Sonneveld, P, van de Loosdrecht, A A, Ossenkoppele, G J, Löwenberg, B, Jongen-Lavrencic, M

“…Large, comprehensive population-based studies in acute myeloid leukemia (AML) are scarce. We conducted a nationwide population-based study on treatment, trial…”
Get full text

miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression by Wang, M, Tan, LP, Dijkstra, MK, van Lom, K, Robertus, J.L, Harms, G, Blokzijl, T, Kooistra, K, van t'Veer, MB, Rosati, S, Visser, L, Jongen-Lavrencic, M, Kluin, PM, van den Berg, A

“…Several miRNAs have been reported to be associated with immunoglobulin heavy chain (IgH) mutation and ZAP-70 expression status in blood samples of B-cell…”
Get full text

P406: ENHANCED SIGNIFICANCE OF FLT3‐ITD RESIDUAL DISEASE DETECTION ON TREATMENT OUTCOME IN ACUTE MYELOID LEUKEMIA by Grob, T., Sanders, M., Vonk, C., Kavelaars, F., Rijken, M., Hanekamp, D., Gradowska, P., Cloos, J., Fløisand, Y., Marwijk Kooy, M. V., Manz, M., Ossenkoppele, G., Tick, L., Havelange, V., Löwenberg, B., Jongen‐Lavrencic, M., Valk, P.

Get full text

BCR ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR ABL-positive cells by JONGEN -LAVRENCIC, M, SALESSE, S, DELWEL, R, VERFAILLIE, C. M

“…The mechanism underlying p210(BCR/ABL) oncoprotein-mediated transformation in chronic myelogenous leukemia (CML) is not fully understood. We hypothesized that…”
Get full text

Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013 by Dinmohamed, A G, Brink, M, Visser, O, Jongen-Lavrencic, M

Get full text

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years by Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Beverloo, H B, Valk, P J M, van Marwijk Kooy, M, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, M-C, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, C, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G, Löwenberg, B

“…The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued…”
Get full text

Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival by Dinmohamed, A G, Szabó, A, van der Mark, M, Visser, O, Sonneveld, P, Cornelissen, J J, Jongen-Lavrencic, M, Rijneveld, A W

“…This nationwide population-based study assessed trends in treatment, trial participation and survival among 1833 adult patients diagnosed with acute…”
Get full text

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial by van de Loosdrecht, A. A., Cremers, E. M. P., Alhan, C., Duetz, C., in ’t Hout, F. E. M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J. W. M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M. C., de Greef, G. E., te Boekhorst, P. A. W., Raaijmakers, M. H. G., van Marwijk Kooy, M., Legdeur, M. C., Wegman, J. J., Deenik, W., de Weerdt, O., van Maanen-Lamme, T. M., Jobse, P., van Kampen, R. J. W., Beeker, A., Wijermans, P. W., Biemond, B. J., Tanis, B. C., van Esser, J. W. J., Schaar, C. G., Noordzij-Nooteboom, H. S., Jacobs, E. M. G., de Graaf, A. O., Jongen-Lavrencic, M., Stevens-Kroef, M. J. P. L., Westers, T. M., Jansen, J. H.

“…A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF…”
Get full text

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome by Janssen, J. J. W. M., Löwenberg, B., Manz, M., Biemond, B. J., Westerweel, P. E., Klein, S. K., Fehr, M., Sinnige, H. A. M., Efthymiou, A., Legdeur, M. C. J. C., Pabst, T., Gregor, M., van der Poel, M. W. M., Deeren, D., Tick, L. W., Jongen-Lavrencic, M., van Obbergh, F., Boersma, R. S., de Weerdt, O., Chalandon, Y., Heim, D., Spertini, O., van Sluis, G., Graux, C., Stüssi, G., van Norden, Y., Ossenkoppele, G. J.

“…Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1…”
Get full text

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS by Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B.

“…More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to…”
Get full text

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry by Dinmohamed, A G, van Norden, Y, Visser, O, Posthuma, E F M, Huijgens, P C, Sonneveld, P, van de Loosdrecht, A A, Jongen-Lavrencic, M

Get full text

The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML by Sun, S M, Rockova, V, Bullinger, L, Dijkstra, M K, Döhner, H, Löwenberg, B, Jongen-Lavrencic, M

“…Acute myeloid leukemia (AML) is a highly heterogeneous disease, characterized by various cytogenetic and molecular abnormalities, many of which may express…”
Get full text

Aberrant expression of miR-9/9 in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG by Nowek, K, Sun, S M, Bullinger, L, Bindels, E M J, Exalto, C, Dijkstra, M K, van Lom, K, Döhner, H, Erkeland, S J, Löwenberg, B, Jongen-Lavrencic, M

“…Aberrant post-transcriptional regulation by microRNAs (miRNAs) has been shown to be involved in the pathogenesis of acute myeloid leukemia (AML). In a previous…”
Get full text

Expression of a passenger miR-9 predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age by Nowek, K, Sun, S M, Dijkstra, M K, Bullinger, L, Döhner, H, Erkeland, S J, Löwenberg, B, Jongen-Lavrencic, M

“…In double-stranded miRNA/miRNA* duplexes, one of the strands represents an active miRNA, whereas another, known as a passenger strand (miRNA*), is typically…”
Get full text

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS by Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine by Hilberink, Jacobien R., van Zeventer, Isabelle A., Chitu, Dana A., Pabst, Thomas, Klein, Saskia K., Stussi, Georg, Griskevicius, Laimonas, Valk, Peter J. M., Cloos, Jacqueline, van de Loosdrecht, Arjan A., Breems, Dimitri, van Lammeren-Venema, Danielle, Boersma, Rinske, Jongen-Lavrencic, Mojca, Fehr, Martin, Hoogendoorn, Mels, Manz, Markus G., Söhne, Maaike, van Marwijk Kooy, Rien, Deeren, Dries, van der Poel, Marjolein W. M., Legdeur, Marie Cecile, Tick, Lidwine, Chalandon, Yves, Ammatuna, Emanuele, Blum, Sabine, Löwenberg, Bob, Ossenkoppele, Gert J., Huls, Gerwin

“…Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk…”
Get full text

MicroRNA signatures characterize multiple myeloma patients by Corthals, S L, Sun, S M, Kuiper, R, de Knegt, Y, Broyl, A, van der Holt, B, Beverloo, H B, Peeters, J K, el Jarari, L, Lokhorst, H M, Zweegman, S, Jongen-Lavrencic, M, Sonneveld, P

Get full text

Effectiveness of azacitidine in higher-risk myelodysplastic syndromes by Dinmohamed, A G, van Norden, Y, van de Loosdrecht, A A, Jongen-Lavrencic, M

Get full text

17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation by Dijkstra, M K, van Lom, K, Tielemans, D, Elstrodt, F, Langerak, A W, van ‘t Veer, M B, Jongen-Lavrencic, M

Get full text

Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus by JONGEN-LAVRENCIC, M, SCHNEEBERGER, P. M, VAN DER HOEVEN, J. G

“…Toxic epidermal necrolysis (TEN), or Lyell's syndrome, is a fulminant bullous dermatitis. TEN is often a drug-induced reaction and virtually any drug class…”
Get full text